6-methyl-5-oxoheptanal | 61447-68-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-methyl-5-oxoheptanal
• 英文别名: 6-methyl-5-oxo-heptanal；γ-isobutyryl-butyraldehyde；γ-Isobutyryl-butyraldehyd；2-Methyl-heptanon-(3)-al-(7)
• CAS: 61447-68-5
• 化学式: C₈H₁₄O₂
• 分子量: 142.198
• InChiKey: FGLCRQZDHJQWES-UHFFFAOYSA-N

物化性质

• 沸点：
  105-109 °C(Press: 20 Torr)
• 密度：
  0.915±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-methyl-5-oxoheptanal 在 盐酸羟胺 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以23%的产率得到2-异丙基吡啶
  参考文献：
  名称：

  Epsztajn, Jan; Bieniek, Adam; Brzezinski, Jacek Z., Polish Journal of Chemistry, 1980, vol. 54, # 2, p. 341 - 347

  摘要：

  DOI：
• 作为产物：
  描述：

  1-异丙基环戊烯 在 溶剂黄146 作用下， 生成 6-methyl-5-oxoheptanal
  参考文献：
  名称：

  Meerwein, Justus Liebigs Annalen der Chemie, 1914, vol. 405, p. 171

  摘要：

  DOI：

文献信息

• Proline-Catalyzed Knoevenagel Condensation/[4+2] Cycloaddition Cascade Reaction: Application to Formal Synthesis of Averufin
  作者：Haibo Tan、Xinzheng Chen、Huiyu Chen、Hongxin Liu、Shengxiang Qiu

  DOI：10.1002/ejoc.201500559

  日期：2015.8

  A remarkable proline-catalyzed method for the construction of biologically interesting oxygen-bridged tricyclic ketal skeletons was uncovered by starting from a variety of readily available cyclic 1,3-diketones and either 1,4- or 1,5-dicarbonyl substrates. The approach, which mimics a biosynthetic Knoevenagel condensation/[4+2] cycloaddition sequence, establishes a viable synthetic strategy for the

  通过从各种现成的环状 1,3-二酮和 1,4-或 1,5-二羰基底物开始，揭示了一种用于构建具有生物学意义的氧桥连三环缩酮骨架的非凡脯氨酸催化方法。该方法模拟了生物合成的 Knoevenagel 缩合/[4+2] 环加成序列，为阿鲁芬的有效形式合成建立了可行的合成策略。
• Neighboring group participation in Lewis acid-promoted [3 + 4] and [3 + 5] annulations. The synthesis of oxabicyclo[3.n.1]alkan-3-ones
  作者：Gary A. Molander、Kimberly O. Cameron

  DOI：10.1021/ja00056a002

  日期：1993.2

  2-(alkoxycarbon)-m-oxabicyclo[3.n.1]alkan-3-ones can be constructed by this process in which two new carbon-carbon bonds are generated. Unusually high regioncontrol is observed, and good to excellent stereochemical control can be achieved at virtually every position on the new carbocycles. Intramolecular neighboring group participation is proposed to explain the unusually high selectivities attained in the annulation

  路易斯酸用作 1,4- 和 1,5- 二羰基亲电试剂与 β-二酮和 β-酮酯的双（三甲基甲硅烷基）烯醇醚环化的催化剂。多种 2-(烷氧基碳)-m-氧杂双环[3.n.1]alkan-3-ones 可以通过该过程构建，其中产生两个新的碳-碳键。观察到异常高的区域控制，并且几乎可以在新碳环的每个位置实现良好到出色的立体化学控制。提出分子内相邻基团参与来解释在环化反应中获得的异常高的选择性
• [EN] CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT<br/>[FR] INHIBITEURS D'AMINES CYCLIQUES BACE-1 RENFERMANT UN SUBSTITUANT HETEROCYCLIQUE
  申请人：SCHERING CORP

  公开号：WO2005014540A1

  公开（公告）日：2005-02-17

  Disclosed are novel compounds of the formula (I)or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is formula (I) X is -0-, -C(R14)2- or -N(R)-; Z is -C(R14)2- or -N(R)-; t is 0, 1, 2 or 3; each R and R2 is independently H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, alkenyl or alkynyl; each R14 is H, alkyl, alkenyl, alkynyl, halo, -CN, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, -OR35, -N(R24)(R25) or -SR35; R41 is alkyl, cycloalkyl, -S02(alkyl), -C(O)-alkyl, -C(O)-cycloalkyl or -alkyl-NH-C(O)CH3; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating cognitive or neurodegenerative diseases with compounds of formula (I). Also disclosed are pharmaceutical compositions and methods of treatment comprising compounds of formula I in combination with other agents useful in treating cognitive or neurodegenerative diseases.

  揭示了具有以下结构的新化合物（I）或其药学上可接受的盐或溶剂，其中R1为结构（I），X为-0-，-C(R14)2-或-N(R)-；Z为-C(R14)2-或-N(R)-；t为0、1、2或3；每个R和R2独立地为H、烷基、环烷基、环烷基烷基、芳基、杂环芳基、杂环烷基、芳基烷基、杂环芳基烷基、杂环烷基烷基、烯基或炔基；每个R14为H、烷基、烯基、炔基、卤素、-CN、卤代烷基、环烷基、环烷基烷基、芳基、杂环芳基、芳基烷基、杂环芳基烷基、杂环烷基烷基、-OR35、-N(R24)(R25)或-SR35；R41为烷基、环烷基、-S02(烷基)、-C(O)-烷基、-C(O)-环烷基或-烷基-NH-C(O)CH3；其余变量如规范中所定义。还揭示了包括化合物的药物组合物（I）的制剂以及使用化合物（I）治疗认知或神经退行性疾病的方法。还揭示了包括化合物（I）的药物组合物和治疗方法，其与治疗认知或神经退行性疾病有用的其他药剂结合使用。
• <i>N</i>-phenyl-substituted pyrrolidines, piperidines and azabicyclics by a tandem reduction-double reductive amination reaction
  作者：Richard A. Bunce、Derrick M. Herron、Jason R. Lewis、Sharadsrikar V. Kotturi

  DOI：10.1002/jhet.5570400115

  日期：2003.1

  formed in high yield and are easily purified. The method has also been extended to the synthesis of fused N-phenylazabicyclics from 2-(3-oxo-propyl)cycloalkanones. A high degree of diastereoselectivity for the trans-fused product is observed in substrates having an ester group α to the cycloalkanone carbonyl. Bicyclic precursors lacking this ester group give mixtures of cis and trans products. Finally

  通过分别在4-和5-氧醛的存在下催化还原硝基苯来合成N-苯基取代的吡咯烷和哌啶。该方法包括还原芳族硝基以得到N-苯基羟胺或苯胺，然后用两个羰基官能团进行还原胺化。单环体系通常以高收率形成并且易于纯化。该方法还扩展到由2-（3-氧代-丙基）环烷酮合成稠合的N-苯基氮杂双环。在具有相对于环烷酮羰基的酯基为α的底物中，观察到对转熔产物的高度非对映选择性。缺少该酯基的双环前体可得到顺式和反式产品。最后，与以前的报道相反，我们证明了在这些反应中苯胺可以代替硝基苯。
• Compositions and methods for modulating angiopoietin-like 3 expression
  申请人：Ionis Pharmaceuticals, Inc.

  公开号：US10875884B2

  公开（公告）日：2020-12-29

  Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease and/or metabolic disease, or a symptom thereof, in an individual in need thereof.

  本文提供了减少动物体内 ANGPTL3 mRNA 和蛋白质表达的方法、化合物和组合物。本文还提供了用于降低动物体内血脂和/或葡萄糖的方法、化合物和组合物。这些方法、化合物和组合物有助于治疗、预防、延缓或改善有需要的个体的心血管疾病和/或代谢疾病中的一种或多种，或其症状。